Q-omics provides the consensus-scored TOGARAM2 profile across patient tissues and cancer cell-line models. TOGARAM2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TOGARAM2 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, TOGARAM2 RNA expression shows 15,270 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, KICH, and UVM as cancer lineages where TOGARAM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TOGARAM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TOGARAM2 survival associations across molecular data types. TOGARAM2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TOGARAM2 RNA expression–survival associations across cancer types. High TOGARAM2 expression shows unfavorable associations in KIRC, KIRP and LAML, but favorable associations in SKCM, BRCA and CESC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TOGARAM2 RNA expression.
This table summarizes TOGARAM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for TOGARAM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TOGARAM2 shows lower tumor expression in KICH, LUAD, LUSC, THCA, KIRP and COAD. The KICH box plot shows higher TOGARAM2 RNA expression in normal versus tumor tissue (log2 FC = −0.152, t-test p < 0.001).
This table shows molecular features associated with TOGARAM2 in patient tissues and cancer cell lines. In patient samples, TOGARAM2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TOGARAM2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
